Background. Leprosy morbidity is increased by 2 pathologic immune reactions, reversal reaction (RR) and erythema nodosum leprosum (ENL).
high M. leprae bacterial load [6] . A pronounced T-helper (Th) 1-type response to M. leprae antigens has been documented in the skin of patients with RR [7] . Persons with history of RR can maintain an altered response to M. leprae antigen that differs from patients with nonreaction leprosy for years after resolution of RR [8] . The other common reaction, ENL, occurs in lepromatous (BL or LL) leprosy with painful subcutaneous nodules and systemic findings, such as fever, arthritis, nephritis, and panniculitis [9] . Its pathogenesis seems to be related to formation and deposition of immune complexes in skin and organs [9] . Risk factors for ENL include LL clinical form and high bacterial load [10] .
The immune reactions of leprosy are typically chronic and recurrent and can require years of treatment with corticosteroids or other immunomodulatory medications [10] . Neurologic sequelae from leprosy reactions can be irreversible even with appropriate therapy, significantly increasing the morbidity and disability due to leprosy [11] . Potential biomarkers have been proposed for RR and ENL but have not been validated for predicting reactions [12, 13] . Transcriptional profiling of skin lesions has shown differences between tuberculoid and lepromatous skin lesions [14] , although these were not studied in relation to systemic immune profiles in blood leukocytes. Increased interferon (IFN) α pathway transcripts in RR lesions suggest its involvement in pathogenesis [15] , and a recent study showed that persons with history of RR had a unique gene expression profile in response to M. leprae antigen in vitro [8] . Studies of the transcriptional profiles of immune cells from subjects with active RR and ENL are needed to understand the systemic immune response during reactions. We hypothesized that RR and ENL are caused by distinctly different immune responses. To test this hypothesis, we generated transcriptional profiles of peripheral blood mononuclear cells (PBMCs) of carefully characterized subjects with symptomatic leprosy immune reactions and matched controls with validation studies including quantitative polymerase chain reaction (qPCR), flow cytometry, and immunohistochemistry.
MATERIALS AND METHODS

Human Subjects
Adult patients with leprosy were enrolled from Hansen's disease treatment centers in Rio Grande do Norte, Brazil. Leprosy clinical forms were assigned by a trained dermatologist (M. d. C. A. P. Q., L. L. M., or M. L. N.) based on Ridley-Jopling criteria [2] . Diagnoses of RR or ENL were based on clinical findings [16, 17] . Excluded from this study were persons with known immunodeficiency or who had received corticosteroids within 7 days or thalidomide within 28 days of enrollment.
Transcript microarrays were obtained from 22 patients with leprosy with immune reaction (11 RR and 11 ENL) and 19 controls without reactions matched to cases for age, sex, leprosy clinical form, and stage of treatment. PBMCs for reversetranscription qPCR validation were derived from a subset of these participants and an additional 28 persons (11 RR, 6 ENL, and 11 controls). Monocyte populations were compared in the different leprosy clinical groups using flow cytometry of PBMCs. Skin biopsy immunohistochemical studies were completed for 16 patients with leprosy (3 RR, 3 ENL, 7 BT controls, and 3 BL/LL controls).
PBMC Isolation and RNA Extraction
PBMCs were isolated from heparinized peripheral blood using a Ficoll-Paque PLUS gradient (GE Healthcare Life Sciences). RNA was isolated using Trizol (Life Technologies) and purified with a RNeasy MinElute Cleanup Kit (Qiagen) with on-column DNase treatment.
Microarray and Analysis
Preparation of RNA for hybridization to Illumina BeadChips (Ambion) was performed at the University of Iowa DNA Core Facility using the manufacturer's protocol. After hybridization, the arrays were washed, blocked, and stained according to the Illumina Whole-Genome Gene Expression Direct Hybridization Assay protocol. BeadChips were scanned with the Illumina iScan System and data collected using GenomeStudio software (Illumina, version 2011). Data sets were compared using Rank Products Analysis (Bioconductor utilities; www. bioconductor.org, last accessed December 1, 2014) to optimize comparison of array groups of small sample size and with variability inherent in human clinical samples [18, 19] . Quantile normalized fluorescence results were analyzed with the RankProd library using RPadvance software in R package (v2.36.0, http://www.r-project.org, last accessed December 1, 2014), considering arrays run on separate days as different origins. The resultant orders were compared with topGene software, with a percentage false-positive (FPR) cutoff of 0.05. Reported fold changes for the array are given as log 2 fold change.
Transcripts with a FPR cutoff ≤0.05 and fold change ≥1.5 were used for pathway analyses. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) Biological Process pathways were generated with Webgestalt (2014, Vanderbilt University) [20] with Bonferroni correction. Ingenuity Pathway Analysis (IPA) (Qiagen) was completed using experimentally observed direct and indirect relationships for humans.
qPCR With Taqman Low Density Arrays
Significantly changed microarray transcripts were selected for validation with Taqman Low Density Arrays. PBMC-derived complementary DNA was applied in duplicate to custom Taqman Low Density Arrays (Life Technologies). Fluorescence was normalized to the array baseline in Expression Suite software (version 1.0; Life Technologies) and mean cycle threshold (Ct) values were compared using 2-tailed t tests. Delta-delta cycle threshold (ΔΔCt) values were converted to fold changes using this calculation: fold change = 2 (−ΔΔCt) .
Immunohistochemistry of Skin Biopsy Specimens
Skin biopsy specimens were collected in formalin and fixed in paraffin. After sectioning, slides were deparaffinized and subjected to antigen retrieval. Sections were stained with rabbit anti-human C1q (clone 9A7; Abcam) and mouse anti-human CD21 (clone EP3093; Abcam) with secondary staining with goat anti-rabbit AlexaFluor488 and goat anti-mouse-AlexaFluor546 (Life Technologies). Stained tissue sections were imaged using a Zeiss Examiner.Z1 AX10 confocal (LSN 7100) microscope and recorded using Zen 2010BSP1 software (Zeiss). Intensity, laser range, and gain were constant. For each biopsy specimen, 2 adjacent 15-section micrographs were obtained 1 mm from the edge of the specimen at the dermal-epidermal border with an additional 2 dermal photographs just internal to the initial photographs. Mean intensities of fluorescence were normalized to the BT group for each day of staining and compared using analysis of variance with Tukey posttest. Imaging and analysis were completed by authors (F. M. A. and M. R. C.) blinded to the group assignment.
Flow Cytometry
A total of 250 000 PBMCs were stained with anti-CD14-allophycocyanin-cyanine 7 (Ebioscience), and 50 000 events were counted using a FACS-Canto II flow cytometer (Becton Dickinson) and recorded with FACSDiva software (Becton Dickinson). Data were analyzed using FlowJo software (v 9.5.3, TreeStar) with monocyte gate and CD14 positivity assigned as in Supplementary Figure 1A . Monocyte populations were compared using analysis of variance with Tukey multiplecomparison tests for normally distributed data, and KruskalWallis test with Dunn multiple comparison for non-normally distributed data.
Ethical Considerations
The study was reviewed and approved by the institutional review boards of the Universidade Federal do Rio Grande do Norte, Brazil's National Ethical Review Board, and Weill Cornell Medical College. The Brazilian institutional review board is registered with the US National Institutes of Health. All participants provided written informed consent for participation in the study.
RESULTS
Study Population
The study population for the transcript microarray included 22 patients with leprosy with immune reaction (11 RR and 11 ENL) matched 1:1 for age, sex, leprosy clinical form, and stage of treatment with a control patient without reaction (Table 1) . PBMCs used for qPCR were from a subset of these subjects and another 28 patients with leprosy. Additional samples included in the RR qPCR validation were RR (n = 11) and non-RR controls (n = 7). Age (mean, 50 vs 51 years; P = .89), sex (59.1% vs 55.6% male; P = .82), and clinical form of leprosy (P = .96) did not differ significantly between RR and non-RR groups. Additional samples included in the ENL qPCR validation were ENL (n = 6) and non-ENL controls (n = 4). Age (45 vs 51 years; P = .33), sex (82.4% vs 60% male; P = .24), and clinical Abbreviations: GO, Gene Ontology; RR, reversal reaction. form of leprosy (P = .47) did not differ significantly different between ENL and non-ENL groups.
Pathway Analysis of Transcriptomes
The first aim of this study was to characterize the transcriptome profiles associated with the transition of leprosy to either RR or ENL. Comparing RR with non-RR controls, there were 275 differentially expressed genes (n = 203 increased and n = 72 decreased in RR). Comparing ENL with non-ENL controls, there were 517 differentially expressed genes (n = 300 increased and n = 217 decreased in ENL). Differentially expressed genes are listed in Supplementary Table 1 . Considering all differentially expressed genes in RR, the top GO Biological Process pathways were related to the immune response: immune response, defense response, immune system process, response to stress, and innate immune response (Table 2) . Consistently, the top 3 KEGG pathways were Staphylococcus aureus infection (adjusted P = 2.56 × 10 −13 ), complement and coagulation cascades (adjusted P = 4.85 × 10 −9 ), and systemic lupus erythematosus (adjusted P = 7.32 × 10 −9 ) ( Table 3) network for RR is shown in Figure 1A and includes pathogen receptors, chemokines and chemokine receptors, and molecules that interact with immunoglobulin. Similar to RR, the top GO Biological Process pathways changed in ENL were related to the immune response: defense response, immune system process, response to bacterium, response to wounding, and immune response ( Table 4 ). The top 3 KEGG pathways were S. aureus infection (adjusted P = 1.9 × 10
), systemic lupus erythematosus (adjusted P = 7.37 × 10 −14 ), and cytokine-cytokine receptor interaction (adjusted P = 8.48 × 10 −10 ) ( Table 5 ). The complement and coagulation pathway (adjusted P = 3.78 × 10 −9 ) was also associated with ENL. These pathways include components of the classic complement pathway, histones, cytokine receptors, and inflammatory response regulators. The top canonical pathways for ENL identified by IPA were granulocyte adhesion and diapedesis (P = 1.46 × 10 −12 ), agranulocyte adhesion and diapedesis (P = 3.64 × 10 −11 ), and interleukin 8 signaling (P = 2.68 × 10 −6 ). IPA identified CCL5 as the most significant upstream regulator of the expression changes in the array (P = 9.78 × 10 −16 ), followed by IFN-γ (P = 8.88 × 10
−15
). The top associated IPA-generated network for ENL is shown in Figure 1B and includes immunoglobulin receptors, pathogen recognition receptors, and chemokines.
Comparison of RR and ENL Transcriptomes
Another aim of this study was to describe the similarities and differences in gene expression in RR and ENL (compared with their respective controls). Considering all differentially expressed genes, there were 379 transcripts unique to ENL, 137 unique to RR, and 138 that had differential expression in both RR and ENL groups (Tables 6-8). Of those genes with increased expression, 104 were unique to RR, 201 unique to ENL, and 99 with increased expression in both RR and ENL groups. Among genes with decreased expression during an immune reaction, 57 were unique to RR, 202 unique to ENL, and 15 with decreased expression in both groups.
A transcript uniquely increased in RR was CXCL10, which has previously been studied in association with RR [12] . Also increased in RR was transglutaminase 2 (TGM2), which is increased in autoimmune disease and may be related to antigen modification [21] . In the RR group, there were increased transcript levels of pattern recognition receptor C-type lectin domain family 7, member A (CLEC7A [dectin-1]), and a scavenger receptor, the macrophage receptor with collagenous structure (MARCO) [22] . There were decreased transcripts of B-cell-associated molecules CD79, CD19, and CD27 and T-cell signaling modulator CCR7. IPA biomarkers analysis identified chemokine (C-X-C motif ) ligand 10 (CXCL10) and Fc fragment of IgE, low affinity II (FCER2) as transcripts with differential levels unique to RR.
Transcripts uniquely increased in ENL included the complement receptors C3AR1 and C5AR1 and 3 ribonucleases; RNASE1, RNASE2, and RNASE3. Uniquely decreased transcripts in ENL included interleukin 10 and cytotoxic tlymphocyte associated protein 4 (CTLA4), modulators of T-cell responses. Decreased CTLA4 and interleukin 10 in ENL could either contribute to the inflammatory cascade observed clinically during ENL or reflect a relatively high level of the inhibitory protein in PBMCs of patients with lepromatous leprosy without ENL. IPA biomarkers analysis identified 20 genes as uniquely differentially expressed in ENL compared with RR including the chemokine ligands CCL3L3 and CXCL8. Abbreviations: ENL, erythema nodosum leprosum; GO, Gene Ontology. Components of the innate immune response were increased in both RR and ENL, including C1q (C1QA, C1QB, and C1QC). Interestingly, both RR and ENL had increased expression of hepcidin (HAMP) and cathelicidin (CAMP) antimicrobial peptides. Defensins were increased in ENL (DEFA1, DEFA1B, DEFA3, and DEFA4) and in RR (DEFA4). Fc receptor-like 3 and Fc receptor-like A were both decreased in RR and ENL groups. IPA biomarkers analysis identified 12 transcripts which could be potential biomarkers for RR or ENL, including CCL2, CCL3, and SOD2. Transcripts increased in PBMCs from both RR and ENL also included FcγR1 (CD64), FPR1 and FPR2, and triggering receptor on myeloid cells 1 (TREM1) and the related molecule triggering receptor expressed on myeloid cells-like 1 (TREML1). FcγR1 recognizes immunoglobulin G; FPR1 and FPR2 recognize formylated peptides produced by bacteria and some mycobacteria [23] .
Increased Monocyte-related Transcripts During RR and ENL
Changes in transcripts could reflect either a change in gene expression within PBMCs or a change in circulating cellular composition. To assess whether monocytosis was a potential contributor to differential expression, we quantified the monocyte population in PBMCs by gating and staining for CD14 (Supplementary Figure 1A) in patients with leprosy with RR (n = 7), ENL (n = 8), or leprosy without reaction (n = 16). Monocytes comprised 13.79%, 19.01%, or 15.77% of PBMCs in RR, ENL, or no reaction, respectively (P = .45) (Supplementary Figure 1B) . Furthermore, the majority of gated monocytes were CD14 + in all groups (mean, 92.78%, 87.76%, or 92.28% in RR, ENL, or no reaction, respectively; P = .54) (Supplementary Figure 1C) . Side scatter/forward scatter and CD14 + measures of monocytes do not confirm a significant difference in the proportion of circulating monocytes between reaction and nonreaction PBMCs.
Confirmation of Differential Gene Expression: Complement Components
Given the current theory of augmented Th1 response to antigen as the etiology of RR, findings of innate immune response as a top GO pathway and complement and coagulation cascade as a top KEGG pathway were interesting and suggestive of potential overlap in immunologic response during RR and ENL. The blue-pink o'gram representation of the array heat map for the complement pathway components of the array is shown in Supplementary Figure 2 . Several components of the classic complement pathway had increased expression in PBMCs from persons with RR or ENL (Table 9) . C1qA, B, and C, complement component 2 (C2); and C1 esterase inhibitor (SERPING1) were increased in RR. C1qA, B, and C and the complement receptors C3AR1 and C5AR1 were increased in ENL. Changes in C1QB, C2, C1 esterase inhibitor, and C5AR1 expression in PBMCs were validated with qPCR ( Table 9 ). The skin is a primary site of RR and ENL signs and symptoms, so we hypothesized that increased expression of C1q in PBMCs during RR or ENL could reflect increased deposition of C1q in skin. Skin biopsy specimens from patients with leprosy obtained as part of diagnostic workup for RR (n = 3), ENL (n = 3), and borderline leprosy without reaction (n = 7 BT and n = 3 BL/LL) were studied with immunohistochemistry. The fluorescent intensity of C1q staining was significantly higher in both RR and ENL compared with nonreaction leprosy (P ≤ .01) (Figure 2 ), indicating increased deposition of C1q in reactional compared with nonreactional leprosy skin lesions.
DISCUSSION
Analysis of RR and ENL transcriptomes demonstrates distinct pathways associated with the immune response. No validated biomarker or effective prophylaxis is currently available for RR and ENL [7, 8, 12, [24] [25] [26] , and gene expression studies are a crucial exploratory method to better understand reaction pathogenesis. Some findings support previously published results on leprosy immunology. Of particular interest was the increased expression of CXCL10 in the RR group, and its identification as a potential RR biomarker by IPA biomarkers analysis, as CXCL10 has previously been proposed as a biomarker for RR [12] . The nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway (KEGG) was associated with ENL, an interesting finding given the association of NOD2 with leprosy in a genome wide association study [27] . IFN-γ was identified as an upstream regulator of differential transcription in PBMCs of RR and ENL, which may be a stimulus for immune cascade of reactions.
Pathway analysis showed a significant involvement of the innate immune system with RR and ENL. HAMP and CAMP antimicrobial peptide transcripts were increased in RR and ENL. CAMP expression is increased by a Toll-like receptor 1/ 2-mediated process, and Toll-like receptor 2 polymorphisms have been associated with increased risk of RR [28] . The complement and coagulation pathway was an unexpected pathway to find enriched in the RR group, given the Th1 augmentation theory of RR pathology, but our results support a potential role in RR pathogenesis. We demonstrated increased deposition of C1q in skin lesions of patients with leprosy with RR or ENL, suggesting that complement is involved in both reaction types systemically and in skin lesions. Interestingly, we did not find a significantly different level of C1q deposition in tuberculoid and lepromatous leprosy lesions, despite the different bacterial burden and immune cell composition in the 2 leprosy poles. That BT and BL/LL controls without immune reaction have similar degree of C1q deposition in tissues supports association of complement deposition with reactions rather than leprosy per se. The increased complement deposition during reactions, compared with baseline pathology due to leprosy, suggests that complement deposition is part of the immune response in RR and ENL.
The frequent association of reactions with recent initiation of anti-M. leprae therapy parallels the pathologic immune activation that can occur when treatment is started for other infectious diseases, such as human immunodeficiency virus and Mycobacterium tuberculosis infection. Patients with tuberculosis who go on to develop immune reconstitution inflammatory syndrome (IRIS) have increased C1q expression at initiation and after 2 weeks of antiretroviral treatment [29, 30] . Patients with tuberculosis and IRIS have increased C1 inhibitor at baseline without further increase in C1 inhibitor 2 weeks after starting antiretroviral therapy, as was seen in controls. Tran et al [30] hypothesized that mycobacterial antigen load may drive the complement activation they observed during tuberculosis with IRIS. PBMCs from patients with leprosy with a history of RR have, in response to stimulation with M. leprae antigen, an increased expression of genes associated with monocyte recruitment and the innate immune response [8] . "Antigen processing and presentation" KEGG pathways were associated with RR and ENL in this microarray analysis, which supports contribution of antigen to RR and ENL pathogenesis. HLA associations have been made with leprosy [31, 32] , although the contribution of HLA expression to antigen presentation and immune response during RR and ENL needs to be described. Our findings of transcriptional differences of HLA genes could inform future studies of HLA types and risk of immune reactions. A major strength of this study is the description of PBMC gene expression from persons with active, untreated immune reactions compared with controls matched for age, sex, and clinical form of leprosy. Matching for stage of leprosy treatment in the array was a control for effects of antileprosy therapy and stage of leprosy disease on gene expression. Furthermore, samples were collected and processed before initiation of immunomodulatory therapies. We were also able to investigate correlation of gene expression differences of C1q in PBMCs to presence in skin during reactions. We minimized potential type 2 errors associated with large-scale array comparisons by Figure 2 . Intensity of fluorescent staining for C1q (A) with representative photographs (B) in skin lesions of reversal reaction (RR; n = 3), erythema nodosum leprosum (ENL; n = 3), borderline tuberculoid (BT) controls (n = 7), and borderline lepromatous (BL)/ lepromatous leprosy (LL) (n = 3) controls. Differences in groups were determined with analysis of variance and Tukey multiple-comparison test. *P ≤ .05; †P ≤ .01; ‡P ≤ .001. Error bars denote standard error of the mean.
applying stringent criteria (FPR, ≤0.05; P ≤ .05; fold change ≥1.5 or ≤−1.5) for transcripts used for functional and biologic pathway analyses. Study limitations include analysis of gene expression in PBMCs rather than whole blood, because conclusions are relevant for the isolated monocyte and lymphocyte populations. The PBMC and biopsy specimens used were not from the same patients, which needs to be considered when assessing experimental conclusions.
We hypothesize that both RR and ENL may have disordered recognition responses to M. leprae antigen with increased production of antibodies or heightened responsiveness to antibodies, with pathology mediated by complement and other components of innate immunity. Differences in the clinical presentation of RR and ENL may be related to several factors, including M. leprae burden and the balance between humoral and cell-mediated immune responses to M. leprae and other antigens. Genetic factors have also been proposed as risk factors for immune reactions [28] . Further investigations of the involvement of innate immunity, including complement and antimicrobial peptides, and IFN-γ-mediated processes are indicated to fully elucidate the pathophysiology of leprosy immune reactions.
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